Skip to main content
    C

    Crispr Therapeutics AG (CRSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $40.37
    -1.87 (-4.43%)

    Market Cap: $4.10B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Crispr Therapeutics AG (CRSP) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Crispr Therapeutics AG (CRSP) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Crispr Therapeutics AG reported EPS of -$1.15, below the -$1.06 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(18/39)
    Avg Surprise
    +25.04%

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.26
    Range-$2.10 - -$0.79
    22 analysts
    Revenue Consensus
    $9.87M
    RangeN/A
    21 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.09
    Range-$1.33 - -$0.73
    7 analysts
    EPS Revisions
    4
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.89-23.5%
    60d ago-$0.89-23.5%
    30d ago-$0.89-23.5%
    7d ago-$1.09+0.1%
    Current-$1.09
    Revenue Consensus
    $11.45M
    Range$300.00K - $42.55M
    7 analysts

    Next Report

    CRSP has an expected report date of Feb 10, 2027.

    Earnings History

    Of the 39 quarters below that had an estimate, CRSP beat 18, missed 20 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $12.67M, up 1325.2% from $889000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.15-$1.06-$1.50 - -$0.46-8.49%MissN/A170 up, 1 downNov 2, 2026$12.67M
    Jun 30, 2026-$0.94-$1.10-$1.44 - -$0.81+14.55%BeatN/A170 up, 1 downAug 3, 2026$10.18M
    Mar 31, 2026-$1.28-$1.23-$1.51 - -$0.81-4.07%MissN/A191 up, 1 downMay 4, 2026$1.46M
    Dec 31, 2025-$1.37-$1.23-$1.67 - -$0.98-11.38%MissN/A165 up, 7 downFeb 12, 2026$864000
    Sep 30, 2025-$1.17-$1.29-$1.67 - -$0.96+9.30%BeatN/A141 up, 0 downNov 10, 2025$889000
    Jun 30, 2025-$1.29-$1.40-$1.78 - -$0.93+7.86%BeatN/A191 up, 1 downAug 4, 2025$892000
    Mar 31, 2025-$1.58-$1.28-$1.74 - -$0.74-23.44%MissN/A170 up, 2 downMay 6, 2025$865000
    Dec 31, 2024-$0.44-$1.19-$1.93 - -$0.74+62.89%Beat-140.0%231 up, 0 downFeb 11, 2025$35.69M
    Sep 30, 2024-$1.01-$1.40-$1.90 - -$0.43+27.86%BeatN/A231 up, 0 downNov 5, 2024$602000
    Jun 30, 2024-$1.49-$1.43-$1.91 - -$1.08-4.20%MissN/A220 up, 0 downAug 5, 2024$517000
    Mar 31, 2024-$1.43-$1.33-$2.07 - $0.80-7.52%MissN/A192 up, 0 downMay 8, 2024$504000
    Dec 31, 2023$1.10$0.05-$2.09 - $1.25N/AN/AN/A221 up, 2 downFeb 21, 2024$201.21M
    Sep 30, 2023-$1.41-$1.95-$2.37 - -$0.73+27.69%BeatN/A221 up, 0 downNov 6, 2023N/A
    Jun 30, 2023-$0.98-$2.10-$2.32 - -$1.56+53.33%BeatN/A230 up, 0 downAug 7, 2023$70.00M
    Mar 31, 2023-$0.67-$1.64-$2.39 - -$0.56+59.15%BeatN/A200 up, 0 downMay 8, 2023$100.00M
    Dec 31, 2022-$1.41-$2.30-$2.66 - -$1.33+38.70%BeatN/A220 up, 0 downFeb 21, 2023$6000
    Sep 30, 2022-$2.24-$2.24-$2.58 - -$1.810.00%In lineN/A220 up, 0 downNov 1, 2022$94000
    Jun 30, 2022-$2.40-$2.21-$2.48 - -$1.89-8.60%Miss-125.4%210 up, 1 downAug 8, 2022$158000
    Mar 31, 2022-$2.32-$1.97-$2.28 - -$1.61-17.77%MissN/A190 up, 0 downMay 9, 2022$940000
    Dec 31, 2021-$1.84-$1.78-$2.17 - -$1.38-3.37%MissN/A210 up, 0 downFeb 15, 2022$12.90M
    Sep 30, 2021-$1.67-$1.76-$2.00 - -$1.39+5.11%BeatN/A21N/ANov 3, 2021$824000
    Jun 30, 2021$9.44$3.12-$1.61 - $10.43+202.56%BeatN/A18N/AJul 29, 2021$900.70M
    Mar 31, 2021-$1.51-$1.47-$1.64 - -$1.20-2.72%MissN/A19N/AApr 27, 2021$539000
    Dec 31, 2020-$1.50-$1.27-$1.40 - -$0.70-18.11%Miss-394.1%18N/AFeb 16, 2021$370000
    Sep 30, 2020-$1.32-$1.19-$1.30 - -$0.87-10.92%Miss-155.0%17N/AOct 28, 2020$148000
    Jun 30, 2020-$1.30-$0.99-$1.32 - -$0.76-31.31%MissN/A15N/AJul 27, 2020$44000
    Mar 31, 2020-$1.15-$1.04-$1.20 - -$0.77-10.58%MissN/A15N/AApr 28, 2020$157000
    Dec 31, 2019$0.51-$0.63-$1.36 - $0.23+180.95%BeatN/A14N/AFeb 12, 2020$77.02M
    Sep 30, 2019$2.40$1.79N/A+34.08%BeatN/A9N/AOct 28, 2019$211.93M
    Jun 30, 2019-$1.01-$0.90-$1.08 - -$0.73-12.22%MissN/A10N/AJul 29, 2019$318000
    Mar 31, 2019-$0.93-$0.90-$1.01 - -$0.79-3.33%MissN/A11N/AApr 29, 2019$328000
    Dec 31, 2018-$0.92-$0.78-$0.89 - -$0.57-17.95%Miss-27158.8%10N/AFeb 25, 2019$115000
    Sep 30, 2018-$1.07-$0.74-$0.85 - -$0.59-44.59%MissN/A9N/ANov 7, 2018$563000
    Jun 30, 2018-$0.82-$0.64-$0.71 - -$0.59-28.13%MissN/A6N/AAug 7, 2018$1.09M
    Mar 31, 2018-$0.62-$0.67-$0.74 - -$0.60+7.46%BeatN/A8N/AMay 8, 2018$1.36M
    Dec 31, 2017$0.00-$0.67-$0.77 - -$0.64+100.51%Beat-99.8%6N/AMar 8, 2018$32.33M
    Sep 30, 2017-$0.62-$0.60-$0.68 - -$0.51-3.33%MissN/A5N/ANov 8, 2017$2.39M
    Jun 30, 2017-$0.56-$0.62-$0.70 - -$0.56+9.68%BeatN/A4N/AAug 10, 2017$3.58M
    Mar 31, 2017-$0.54-$0.65N/A+16.92%BeatN/AN/AN/AMay 11, 2017$2.70M
    Dec 31, 2016$1.42-$0.49N/A+389.80%BeatN/AN/AN/AMar 10, 2017$2.34M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.41, after -$4.37 the year before. It was $1.05 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.41N/A
    Dec 31, 2024-$4.37N/A
    Dec 31, 2023-$1.96N/A
    Dec 31, 2022-$8.37-289.4%
    Dec 31, 2021$4.42N/A
    Dec 31, 2020-$5.27-643.3%
    Dec 31, 2019$0.97N/A
    Dec 31, 2018-$3.43N/A
    Dec 31, 2017-$1.72-263.5%
    Dec 31, 2016$1.05N/A

    Frequently Asked Questions About CRSP

    When is Crispr Therapeutics AG's next earnings date?

    Crispr Therapeutics AG's next earnings report is expected for Feb 10, 2027.

    Did CRSP beat earnings estimates last quarter?

    No. Crispr Therapeutics AG reported EPS of -$1.15 for the quarter ended Sep 30, 2026, below the -$1.06 estimate by 8.49%.

    What EPS do analysts expect from CRSP next quarter?

    The consensus EPS estimate for Crispr Therapeutics AG for the quarter ending Dec 31, 2026 is -$1.26 from 22 analysts, with estimates from -$2.10 to -$0.79.

    How often does CRSP beat earnings estimates?

    Crispr Therapeutics AG beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +5.90%.